JACK WOLFE SINGER, MD
Osteopathic Medicine at 9 Ave, Seattle, WA

6420374, Jul 16, 2002

Nov 6, 1996

08/743683

James A. Bianco - Seattle WA
Jack W. Singer - Seattle WA

Fred Hutchinson Cancer Research Center - Seattle WA

A61K 3152

514263, 514264

A family of compounds effective in suppressing lymphocyte activation is comprised of 7-(oxoalkyl)1,3-dialkyl xanthines, other than denbufylline, of the formula in which R and R are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is comprised of compounds of the formula wherein at least one of R and R is either a) a branched hydroxyalkyl group of the formula in which R stands for an alkyl group with 1 to 3 carbon atoms and n stands for a whole number from 2 to 5, the other R or R group that lay optionally be present stands for a hydrogen atom or an aliphatic hydrocarbon group R with up to 6 carbon atoms, whose carbon chain may be interrupted by up to 2 oxygen atoms or may be substituted with a hydroxy or oxo group, or b) an oxoallyl group of the formula wherein R is C -C and p is 2, 3 or 4, the remaining R or R being as defined above, and R is an alkyl group C -C ; The suppression of lymphocyte activation is indicated in humans afflicted with autoimmune disease.

5929081, Jul 27, 1999

Jun 7, 1995

8/485320

Paul A. Brown - Snohomish WA
Stuart L. Bursten - Snoqualmie WA
Glenn C. Rice - Seattle WA
Jack W. Singer - Seattle WA

Cell Therapeutics Inc. - Seattle WA

A61K 3152, A61K 31535, A61K 3151, A61K 3144

514263

There is disclosed a method for: (1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply: (2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies; (3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells; (4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells; (5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty; (6) suppressing atherogenesis, coronary artery disease and other vasculopathies due to atherogenesis; and (7) suppressing tumor growth via paracrine or autocrine mediated responses to PDGF, FGF EGF or VEGF that is useful for treating or preventing progression of tumors such as breast cancer stimulated through overexpression of her-2-neu receptor, wherein the inventive method comprises administering a compound that inhibits signal transduction through cellular accumulation of non-arachidonyl phosphatidic acid (PA) selected from the group consisting of 1-o-octadecanyl 2-oleoyl PA (687), 1-oleoyl 2-linoleoyl PA (697 or 698), 1-o-octadecanyl 2-linoleoyl PA (681), 1-o-octadecanyl-9,12-dienyl 2-linoleoyl PA (679), 1-myristoyl 2-oleoyl PA (645), 1-o-myristoyl 2-stearoyl PA (633), 1,2-sn-dilinoleoyl PA (695), 1-oleoyl 2-linoleoyl PA (697), 1-stearoyl 2-oleoyl PA (701), 1-o-oleoyl 2-20:4 PA (707), 1-o-linoleoyl 2-20:4 PA (705), 1-o-linoleoyl 2-20:5 PA (703), and combinations thereof.

5856331, Jan 5, 1999

Oct 10, 1997

8/948747

Stuart L. Bursten - Snoqualmie WA
Jack W. Singer - Seattle WA
Glenn C. Rice - Seattle WA

Cell Therapeutics, Inc. - Seattle WA

A61K 31415, A61K 3142, A61K 31425, A61K 3152

514263

There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).

5585380, Dec 17, 1996

Jan 25, 1995

8/378109

James A. Bianco - Seattle WA
Stuart L. Bursten - Snoqualmie WA
Jack W. Singer - Seattle WA

Fred Hutchinson Cancer Research Center - Seattle WA

A61K 3152, A61K 3150

514263

The specification discloses methods for modulating cellular metabolism in a subject, modulating being desirable to mitigate a condition of the subject. Disclosed methods include processes for administering to said subject an effective amount of a compound of the formula ##STR1## wherein one and only one of R. sup. 1 and R. sup. 3 is a straight-chain or branched-chain. omega. -hydroxyalkyl (5-8C), or is a branched-chain (. omega. -1)-hydroxyalkyl (5-8C), or is an (. omega. -1)-oxoalkyl (5-8C), or is an (. omega. ,. omega. -1) or (. omega. -1,. omega. -2)-dihydroxyalkyl (5-8C), or is an alkenyl substituent (5-8C), and the other is alkyl (1-12C) optionally containing one or two non-adjacent oxygen atoms in place of C.

5670507, Sep 23, 1997

Jan 27, 1995

8/379232

Glenn C. Rice - Seattle WA
Jack W. Singer - Seattle WA

Cell Therapeutics, Inc. - Seattle WA

A61K 3152, A61K 31565, A61K 3144, A61K 3147

514263

There is disclosed a method for reversing the multiple drug resistant (MDR) phenotype in tumors insensitive to hydrophobic chemotherapeutic drugs due to over expression of mdr-1, comprising administering an effective amount of a long chain amino alcohol compound. There is further disclosed a method for preventing the development of MDR during cancer chemotherapy treatments, comprising administering during cancer chemotherapy treatments an effective amount of a long chain amino alcohol compound.

5567704, Oct 22, 1996

Jun 1, 1995

8/457683

James A. Bianco - Seattle WA
Paul Woodson - Bothell WA
David Porubek - Edmonds WA
Jack Singer - Seattle WA

Cell Therapeutics, Inc. - Seattle WA

A61K 3152

514263

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an. omega. -1 alcohol of a straight chain alkyl (C. sub. 5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating baldness.

5965564, Oct 12, 1999

Mar 20, 1998

9/044976

James A. Bianco - Seattle WA
Paul Woodson - Bothell WA
David Porubek - Edmonds WA
Jack Singer - Seattle WA

Cell Therapeutics, Inc. - Seattle WA

A61K 3152

514263

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an. omega. -1 alcohol of a straight chain alkyl (C. sub. 5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.

5629315, May 13, 1997

Jun 1, 1995

8/456900

James A. Bianco - Seattle WA
Paul Woodson - Bothell WA
David Porubek - Edmonds WA
Jack Singer - Seattle WA

Cell Therapeutics, Inc. - Seattle WA

A61K 3152

514263

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an. omega. -1 alcohol of a straight chain alkyl (C. sub. 5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.

2003021, Nov 20, 2003

May 9, 2003

10/434097

Stuart Bursten - Snoqualmie WA, US
Jack Singer - Seattle WA, US
Glenn Rice - Seattle WA, US

Cell Therapeutics,Inc.

A61K031/55, A61K031/53, A61K031/519, A61K031/522, A61K031/517

514/263360, 514/260100, 514/241000, 514/217110, 514/266100, 514/220000, 514/265100, 514/215000

There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).